Beckwith-Wiedemann Syndrome

This PatientPlus article is written for healthcare professionals so the language may be more technical than the condition leaflets. You may find the abbreviations list helpful.

Beckwith-Wiedemann syndrome is an overgrowth disorder with:

  • Macroglossia
  • Abdominal wall defects
  • Visceromegaly

It was first described in 1964 by Dr H R Wiedemann, a geneticist from Kiel in Germany.[1] Dr J Bruce Beckwith, a paediatric pathologist working in California, also described it in 1969.[2] The severity of effect on the child is highly variable, with the majority minimally affected.

Save time & improve your PDP on Patient.co.uk

  • Notes Add notes to any clinical page and create a reflective diary
  • Track Automatically track and log every page you have viewed
  • Print Print and export a summary to use in your appraisal
Click to find out more »

The underlying cause is unclear. 80% of cases have genotypic abnormalities on the distal portion of chromosome 11p. The reported pattern of inheritance is autosomal dominance with variable expression. There is contiguous gene duplication at band 11p.15.5.[3] This is always derived from the patient's father, whereas translocation and inversion are invariably derived from the mother. There appears to be aberrant genomic imprinting resulting from a defective or absent copy of the maternally derived gene - uniparental disomy.

Most sporadic cases lack apparent cytogenetic abnormalities. Only 2% carry inversions, translocations or deletions. 20% of sporadic cases have uniparental disomy.[4] 50% have loss of methylation.
Most patients with Beckwith-Wiedemann syndrome (BWS) show biallelic expression of IGF2 (insulin-like growth factor 2) in various tissues - see below under Presentation.

Incidence

Clusters in families in 15% of cases. Most are sporadic.
1 in 15,000 in the USA.[5] Approximately 1 in 13,700 for rest of Western world. There is no predilection for race or gender.

Recent work has suggested an association between genetic imprinting disorders (such as BWS and Angelman's syndrome) and children conceived with assisted reproduction techniques (ARTs) such as in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI).[6][7] 1-3% of births result from these techniques, and the figure is rising. Studies from Britain, France and the USA showed unexpectedly high numbers of BWS cases in children conceived this way.[8][9]

Increasingly commonly diagnosed at prenatal ultrasound.[10] Suspicious features include:

  • Increased abdominal circumference
  • Large kidneys
  • Large placenta, raised amniotic fluid volume
  • Protruding tongue
  • Large for gestational age fetus
  • Raised alpha-fetoprotein with omphalocele

Symptoms

  • Hypoglycaemia
  • Poor feeding
  • Lethargy
  • Problems with breathing, eating and speech, relating to the severity of macroglossia

Signs

  • Growth
    • Large for gestational age; the overgrowth in BWS is often the result of increased IGF 2 action in the tissues. Birth weight and length are increased. Hemihypertrophy can be seen, where one part of the body, or usually all or part of one side of the body is enlarged. This often becomes apparent in later childhood.
    • Accelerated growth (on 90th centile or above)
  • Abdominal wall defects
  • Visceromegaly
    • Enlarged liver, kidneys, pancreas and spleen are found
  • Facial abnormalities
    • Large, prominent eyes
    • Creases in ear lobes and pit behind the upper ear
    • Pinna abnormalities, low-set ears
    • Raised fontanelle, prominent occiput
    • Metopic ridge, prominent on forehead due to early closure of fontanelle
  • Others
  • X-ray long bones
  • Blood sugar testing
  • X-ray, ultrasound, CT/MRI scan of abdomen
  • Chromosome analysis

There is an increased risk of tumour development in children with BWS:

  • The incidence of malignant tumours in reported cases is 5-10%.
  • The most common of these is Wilms' nephroblastoma. This occurs in 5-7%. Others are hepatoblastoma and adrenal tumours. Neuroblastomas are less common.
  • The risk of cancer is age-dependent with most occurring by age 4 years. 95% have occurred by the age of 8 years.[12]

General measures

Screening for tumours:[8][13]

  • The child should have alpha-fetoprotein levels (marker for hepatoblastoma) measured every 6 weeks until 3 years old.[14]
  • Also, abdominal ultrasound scan every 3 months until 8 years old.[15][16]

Pharmacological

  • Hypoglycaemia should be rigorously avoided and treated, when necessary.
  • Diazoxide can be used to inhibit insulin secretion. Paediatric dose of 5-15 mg/kg per day, divided 8-12-hourly.

Surgical

  • If the tongue protrudes and interferes with speech and dental development, the child should be considered for reduction surgery before 4 years old.
  • Abdominal wall defects will need early neonatal repair. Testes may need bringing down within the scrotum.

Most can be anticipated and managed:

  • Premature delivery
  • Monozygotic twinning (usually female and discordant)
  • Neonatal hypoglycaemia; uncontrolled hypoglycaemia in infancy is thought to be the major aetiological factor in the reported low IQ in BWS, rather than congenital malformation.

Children who survive infancy do well. There is a 20% infant mortality rate from complications of prematurity, hypoglycaemia and, more rarely, cardiomyopathy.[9] The older the child becomes, the more normal they appear. Most children have very subtle problems, which do not affect their quality of life.

Further reading & references

  1. Wiedemann HR; The EMG-syndrome: exomphalos, macroglossia, gigantism and disturbed carbohydrate metabolism. Z Kinderheilkd. 1969;106(3):171-85.
  2. Beckwith J. Macroglossia, omphalocoele, adrenal cytomegaly, gigantism and hyperplastic visceromegaly. Birth Defects, 1969.(5) 188; Original descriptive paper
  3. Beckwith-Wiedemann Syndrome, Online Mendelian Inheritance in Man (OMIM)
  4. Bestor TH; Imprinting errors and developmental asymmetry. Philos Trans R Soc Lond B Biol Sci. 2003 Aug 29;358(1436):1411-5.
  5. Ferry RJ; Beckwith-Wiedemann Syndrome. eMedicine, May 2009.
  6. Gosden R, Trasler J, Lucifero D, et al; Rare congenital disorders, imprinted genes, and assisted reproductive technology. Lancet. 2003 Jun 7;361(9373):1975-7.
  7. Klemetti R, Gissler M, Sevon T, et al; Children born after assisted fertilization have an increased rate of major congenital anomalies. Fertil Steril. 2005 Nov;84(5):1300-7.
  8. Beckwith JB; Children at increased risk for Wilms tumor: monitoring issues. J Pediatr. 1998 Mar;132(3 Pt 1):377-9.
  9. Pettenati MJ, Haines JL, Higgins RR, et al; Wiedemann-Beckwith syndrome: presentation of clinical and cytogenetic data on 22 new cases and review of the literature. Hum Genet. 1986 Oct;74(2):143-54.
  10. Williams DH, Gauthier DW, Maizels M; Prenatal diagnosis of Beckwith-Wiedemann syndrome. Prenat Diagn. 2005 Oct;25(10):879-84.
  11. Grati FR, Turolla L, D'Ajello P, et al; Grati FR, Turolla L, D'Ajello P, et al; Chromosome 11 segmental paternal isodisomy in amniocytes from two fetuses with omphalocoele: new highlights on phenotype-genotype correlations in Beckwith-Wiedemann syndrome. J Med Genet. 2007 Apr;44(4):257-63. Epub 2007 Jan 26.
  12. DeBaun MR, Tucker MA; Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998 Mar;132(3 Pt 1):398-400.
  13. The Wilms Tumour Surveillance Working Group. Surveillance for Wilms Tumour in at-risk individuals - pragmatic recommendations for Best Practice; April 2005
  14. Clericuzio CL, Chen E, McNeil DE, et al; Serum alpha-fetoprotein screening for hepatoblastoma in children with Beckwith-Wiedemann syndrome or isolated hemihyperplasia. J Pediatr. 2003 Aug;143(2):270-2.
  15. Tan TY, Amor DJ; Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J Paediatr Child Health. 2006 Sep;42(9):486-90.
  16. McNeil DE, Brown M, Ching A, et al; Screening for Wilms tumor and hepatoblastoma in children with Beckwith-Wiedemann syndromes: a cost-effective model. Med Pediatr Oncol. 2001 Oct;37(4):349-56.
Original Author: Dr Hayley Willacy Current Version:
Last Checked: 11/12/2009 Document ID: 1851  Version: 21 © EMIS

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.